Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 13/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.59 |
| ▸ | CDK2 | P24941 | 13/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411866 | 0.91 | GSK3B (0.54) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3410522 | 0.89 | PIK3CD (0.66) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3410536 | 0.84 | GSK3B (0.58) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3409524 | 0.83 | GSK3B (0.75) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3404644 | 0.81 | GSK3B (0.60) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3431749 | 0.81 | GSK3B (0.70) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3405311 | 0.79 | PIK3CD (0.66) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL3410625 | 0.78 | CDK5 (0.66) | PIK3CDCDK5CDK5R1 | |
| SCHEMBL3410562 | 0.78 | CCNE2 (0.56) | GSK3BCCNE2CCNE1CDK2PIK3CD | |
| SCHEMBL11992016 | 0.78 | LMNA (0.55) | GSK3BCCNE2CCNE1CDK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | claimed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | claimed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | claimed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | claimed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | GSK3B 3129/4885CCNE2 2451/4885CCNE1 2616/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | GSK3B 3129/4885CCNE2 2451/4885CCNE1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.